Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €16.99 EUR
Change Today +0.222 / 1.32%
Volume 0.0
As of 4:01 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (D4S) Snapshot

Open
€16.95
Previous Close
€16.77
Day High
€17.02
Day Low
€16.87
52 Week High
08/5/15 - €19.68
52 Week Low
01/9/15 - €11.15
Market Cap
12.0B
Average Volume 10 Days
332.0
EPS TTM
--
Shares Outstanding
709.0M
EX-Date
09/28/15
P/E TM
--
Dividend
€59.99
Dividend Yield
2.63%
Current Stock Chart for DAIICHI SANKYO CO LTD (D4S)

Related News

No related news articles were found.

daiichi sankyo co ltd (D4S) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (D4S) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s generic pharmaceuticals include olmesartan, azelnidipine, and amlodipine antihypertensive agents; loxoprofen, an anti-inflammatory analgesic; levofloxacin, a synthetic antibacterial agent; esomeprazole for ulcer treatment; memantine and donepezil for treating alzheimer’s disease; pravastatin and atorvastatin antihyperlipidemic agents; carvedilol for treating hypertension, angina pectoris, and chronic heart failure; iohexol to enhance visibility of diagnostic X-ray imaging; silodosin for treating dysuria; laninamivir for anti-influenza treatment; edoxaban, an anticoagulant; teneligliptin and pioglitazone type 2 diabetes mellitus inhibitors; denosumab for treating bone complications; denosumab for treating osteoporosis; and prasugrel, an antiplatelet agent. Its generic pharmaceuticals also comprise colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus indication, as well as iron sucrose and ferric carboxymaltose injections for treating anemia. The company also provides over the counter products, such as Lulu, combination cold remedy; Daiichi Sankyo Ichoyaku, a multi-ingredient digestive remedy; Loxonin S, an antipyretic analgesic; Patecs, an antiphlogistic analgesic for external use; and Transino for treating melisma. In addition, it offers ActHIB, a haemophilus influenzae type b vaccine; Rotarix, a rotavirus vaccine; Influenza HA Vaccine; and Live Attenuated Measles/Rubella Combined Vaccine. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

Founded in 1899

daiichi sankyo co ltd (D4S) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥123.0M
Compensation as of Fiscal Year 2015.

daiichi sankyo co ltd (D4S) Key Developments

Daiichi Sankyo to Spend USD 79.7 Million to Expand Domestic Vaccine Plant

Daiichi Sankyo (Japan) plans to spend approximately JPY 10 billion (USD 79.7 million) to expand its domestic vaccine plant. The new plant is expected to manufacture new and seasonal vaccines. Japan produces slightly more than JPY 200 billion in vaccines every year, with demand expected to remain stable for highly effective new products that cause little pain, as well as routine immunisations.

Daiichi Sankyo Company, Limited Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal 2015; Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2015; Revised Earnings Guidance for the Year Ending March 31, 2016

Daiichi Sankyo Company, Limited provided dividend guidance for the second quarter and full year of Fiscal 2015. For the second quarter, the company expects to pay dividend of JPY 40 per share against JPY 30 per share paid a year ago. For the full year, the company expects to pay dividend of JPY 30 per share against JPY 30 per share paid a year ago. The company reported consolidated earnings results for the first quarter ended June 30, 2015. Revenue was JPY 238,417 million against JPY 213,706 million last year. Operating profit was JPY 49,126 million against JPY 32,790 million last year. Profit before tax was JPY 45,194 million against JPY 32,695 million last year. Profit from continuing operations was JPY 34,090 million or JPY 49.66 per diluted share against JPY 20,892 million or JPY 30.58 per diluted share last year. Profit attributable to owners of the company was JPY 34,932 million or JPY 49.66 per diluted share against JPY 19,986 million or JPY 28.34 per diluted share last year. Net cash flows from operating activities were JPY 25,721 million against JPY 17,258 million last year. Acquisitions of property, plant and equipment was JPY 7,419 million against JPY 7,533 million last year. Acquisition of intangible assets was JPY 19,567 million against JPY 5,051 million last year. Increase of the revenue mainly owed to growth in sales of mainstay products in Japan, the U.S., Asia and South and Central America, and to the positive impact of currency movements (valued at about JPY 12.4 billion). Operating profit increase reflected not only an increase in gross profit but also decreases in selling, general and administrative expenses. Increase in profit before tax was not as substantial as the operating profit increase owing to an increase in financial expenses resulting from factors including the payments with regard to the sale of Sun Pharma shares. The substantial increase in profit attributable to owners of the company was the result of the increase in profit before tax and other factors such as a decrease in the amount of income taxes. Capital expenditure was JPY 5.8 billion against JPY 5.2 billion last year. The company revised consolidated earnings guidance for the year ending March 31, 2016. The company expects revenue of JPY 950,000 million, operating profit of JPY 120,000 million, profit before tax of JPY 115,000 million, profit attributable to owners of the company of JPY 75,000 million or JPY 108.12 per basic share against previous guidance for revenue of JPY 920,000 million, operating profit of JPY 100,000 million, profit before tax of JPY 95,000 million, profit attributable to owners of the company of JPY 60,000 million or JPY 85.22 per basic share. In terms of revenue, the launch of a generic product following the expiry of the patent for Welchol® at Daiichi Sankyo Inc. in the U.S. is now expected to be delayed more than previously anticipated. In addition, further expansion in sales of products including Injectafer® at Luitpold Pharmaceuticals is expected. In light of these circumstances, the forecast for revenue has been revised upward by JPY 30.0 billion. With respect to operating profit and profit before tax, in light of an expected gross profit increase due to the expansion in revenue, the forecasts for operating profit and profit before tax have both been revised upward by JPY 20.0 billion. Profit attributable to owners of the company has been revised upward by JPY 15.0 billion in light of an increase in profit for the year resulting from the profit before tax, among other factors. This will be a substantial increase of JPY 46.5 billion against profit attributable to owners of the company of continuing operations in fiscal 2014. The company expects capital expenditure of JPY 30.3 billion.

Daiichi Sankyo Company, Limited, Q1 2016 Earnings Call, Jul 31, 2015

Daiichi Sankyo Company, Limited, Q1 2016 Earnings Call, Jul 31, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
D4S:GR €16.99 EUR +0.222

D4S Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $5.94 USD +0.10
BioMerieux €101.05 EUR -1.00
Exelixis Inc $6.05 USD -0.04
Infinity Pharmaceuticals Inc $9.28 USD +0.16
Ipsen SA €60.76 EUR +0.29
View Industry Companies
 

Industry Analysis

D4S

Industry Average

Valuation D4S Industry Range
Price/Earnings 27.6x
Price/Sales 1.7x
Price/Book 1.3x
Price/Cash Flow 4.9x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.